# Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Canonical URL: https://biopharmsignal.com/news/JAGX/jaguar-health-announces-acceptance-of-two-late-breaking-abstracts-for-liquid-oral-crofelemer-treatment-of-intestinal-failure-in-pediatric-patients-at-the-european-society-for-pediatric-gastroenterology-hepatology-and-nutrition-espghan
Ticker: JAGX
Company: Jaguar Health
Source: Jaguar Health
Published: 2026-04-24 12:30 EST
Original Source URL: https://jaguarhealth.gcs-web.com
## Summary

Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS) Jaguar has received orphan drug designations for MVID & SBS in the US and EU Jaguar has also completed enrollment of pediatric MVID

## Article Body
Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS) Jaguar has received orphan drug designations for MVID & SBS in the US and EU Jaguar has also completed enrollment of pediatric MVID
## Recent Company News
- 2026-05-28 14:00 EST — [Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders](https://biopharmsignal.com/news/JAGX/jaguar-health-research-in-ethnobotanical-medicine-helps-advance-crofelemer-development-for-genetically-defined-rare-congenital-gastrointestinal-disorders) — Source: Jaguar Health
- 2026-05-27 13:00 EST — [Jaguar Health Compliant with Nasdaq Bid Price Rule](https://biopharmsignal.com/news/JAGX/jaguar-health-compliant-with-nasdaq-bid-price-rule) — Source: Jaguar Health
- 2026-05-20 20:40 EST — [Jaguar Health Reports First Quarter 2026 Financials](https://biopharmsignal.com/news/JAGX/jaguar-health-reports-first-quarter-2026-financials) — Source: Jaguar Health
- 2026-05-20 13:00 EST — [Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference](https://biopharmsignal.com/news/JAGX/jaguar-health-to-hold-investor-webcast-may-26-regarding-q1-2026-financials-and-corporate-updates-jaguar-ceo-lisa-conte-presenting-may-28-at-lytham-partners-spring-2026-investor-conference) — Source: Jaguar Health
- 2026-05-19 13:00 EST — [Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer](https://biopharmsignal.com/news/JAGX/jaguar-health-announces-active-treatment-only-continuation-of-pivotal-multicenter-clinical-trial-in-pediatric-patients-with-microvillus-inclusion-disease-mvid-to-support-a-new-drug-application-nda-for-liquid-oral-crofelemer) — Source: Jaguar Health
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)